BioSpace News Archive

Onconova Therapeutics, Inc. announced that the Company intends to release its second quarter 2023 financial results on Thursday, August 10, 2023.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT) today announced the receipt of a Study May Proceed letter from the U.S. Food and Drug Administration (FDA), for a Phase 1/2 dose escalation study of ONCT-534, a novel dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer (mCRPC) who have relapsed or are refractory to approved androgen receptor signaling inhibitors (ARSIs).

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today reported its financial results for the quarter ended June 30, 2023 and provided its financial guidance for the year.

Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”) today announced its financial results for the three-month period ended June 30, 2023 (“the second quarter of 2023”) as compared to the three-month period ended June 30, 2022 (“the second quarter of 2022” or “the prior year period”).

Amgen announced financial results for the second quarter of 2023.

Artivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced its financial results for the second quarter ended June 30, 2023.

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2023.

Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the quarter ended June 30, 2023, and provided a business update.

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended June 30, 2023.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, reported its second-quarter 2023 financial results.